News Another 340B lawsuit gets underway, in Illinois Three pharma groups have opened a new front in their legal challenge to the federal 340B drug pricing programme in the US.
News Novartis weathers Entresto slump with return to growth Novartis saw sales grow 3% in the second quarter, returning to growth after a 1% fall in the first quarter caused by generic competition to Entresto.
News England to start screening newborns for rare disease SMA All newborns in England will be screened for rare muscle-wasting disease spinal muscular atrophy from 2027, in a landmark move for patients.
News AI specialist Chai Discovery raises $400m Fresh from an alliance with Novartis, Chai Discovery has raised $400 million in third-round funding for its AI-based molecular design platform.
Oncology ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad In a conversation at ASCO 2026, Dr Fred Saad of the University of Montreal shared some insights from a subgroup analysis of Pluvicto
News Novartis snaps up UK ADC developer Myricx Bio Novartis has reached a deal to buy Myricx Bio for up to $1.5bn, giving it control of the London, UK, start-up's ADC platform.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.